About US
Contact us
-
BMS faces shareholder opposition to $74bn Celgene acquisitionBristol-Myers Squibb’s (BMS) proposed $74bn acquisition of Celgene is under threat as its two main shareholders, Wellington Management and Starboard Value, are opposing the deal. Wellington Managemen2019/3/4
-
Maze Therapeutics raises $191m to support genetic researchMaze Therapeutics, a start-up with focus on translating genetic insights into new medicines, has been launched operations in the by Third Rock Ventures. Alongside other investors including RCH Ventur2019/3/1
-
Sarepta exercises option to acquire Myonexus for $165mUS rare disease gene therapy company Sarepta has exercised its right from an exclusive partnership to acquire another gene therapy company Myonexus. Sarepta will pay $165m to Myonexus shareholders af2019/3/1
-
AstraZeneca, Merck's Lynparza posts pancreatic cancer win in another PARP-class firstAstraZeneca and Merck’s Lynparza has already led its class into two disease areas, and now it’s looking to make it three. Tuesday, the companies said their PARP inhibitor hadtoppedplacebo at staving2019/2/28
-
Former Novartis executive wins $1.5M in whistleblower retaliation lawsuitMore than four years after a former executive at Novartis sued thedrugmakerclaiming she lost her job for suggesting a drug study might be a type of kickback, a jury has sided in her favor. Min Amy Gu2019/2/28
-
Ipsen to buy Clementia Pharmaceuticals in $1bn dealFrench pharmaceutical company Ipsen has agreed to acquire Canada-based Clementia Pharmaceuticals for an initial aggregate cash consideration of $1.04bn to boost its rare disease portfolio. The terms2019/2/27
-
GE to divest its Biopharma business to Danaher for $21.4bnUS-based conglomerate General Electric (GE) has entered into a definitive agreement to divest its Biopharma business to science and technology innovator Danaher for approximately $21.4bn. As per the2019/2/27
-
Roche to acquire gene therapy specialist Spark Therapeutics for $4.8bnRoche has signed a definitive merger agreement to acquire all outstanding shares of US-based gene therapy companySpark Therapeuticsfor $114.50 per share, corresponding to a total of around $4.8bn on2019/2/26
-
AstraZeneca announces its Brilinta reduced MACE in CAD and type 2 diabetes patientsGlobal pharmaceutical company AstraZeneca has announced its drug Brilinta (ticagrelor) in combination with aspirin has met its primary endpoint, a statistically significant reduction in major adverse2019/2/26
-
Congressman aims to break pharma’s insulin ‘pricing monopoly’ by legalizing Canadian importsU.S. legislators have been introducing bills left and right proposing a variety of methods for bringing down drug prices. Now,Vermont's congressman is zeroing in on a specific class of diabetes medic2019/2/25